TC BioPharm (TCBP) declared a special dividend of 0.25 ADS per ADS held, pending shareholder approval on December 30, 2024. The company, focused on gamma-delta T-cell cancer therapies, is conducting pivotal clinical trials for acute myeloid leukemia (AML) using its CryoTC technology. Despite the dividend announcement, TCBP stock fell 1.94% pre-market.
ImmunityBio has announced the FDA’s approval of ANKTIVA for treating non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) who have not responded to BCG therapy. This approval marks the company’s transition to a commercial biotech with the potential to generate revenue. Additionally, it unlocks expansion opportunities for ANKTIVA in treating acute myeloid leukemia (AML) and platinum-resistant ovarian cancer (PROC). Despite the risks associated with competition and the need for further clinical trials, the FDA approval and potential expansions present promising investment opportunities.
